David Altshuler - 22 Jan 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Reporting relationship: EVP, Chief Scientific Officer
Issuer ticker: VRTX
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jan 2026, 16:10:03 UTC
Prior SEC filing: 19 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Christiana Stevenson, Attorney-in-Fact

Key filing fact

David Altshuler filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 26 Jan 2026.

Key facts

This page summarizes David Altshuler's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 Jan 2026, 16:10.

Change

Previous filing in this sequence was filed on 19 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001550395 Primary reporting owner

ALTSHULER DAVID

Relationship: EVP, Chief Scientific Officer
Address: C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
Signature: /s/ Christiana Stevenson, Attorney-in-Fact
Signature date: 26 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRTX transaction

Common Stock

Award

Transaction value: $0
Shares: +7,866
Change %: +34%
Price: $0.000000
Shares after: 31,149
Date: 22 Jan 2026
Ownership: Direct
Footnotes: F1

VRTX transaction

Common Stock

Award

Transaction value: $0
Shares: +3,328
Change %: +11%
Price: $0.000000
Shares after: 34,477
Date: 22 Jan 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

Footnote F2

Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.